Renalytix Plc (AIM:RENX)

Market Cap	10.27M -64.6%
Revenue (ttm)	2.45M +35.1%
Net Income	-14.79M
EPS	-0.04
Shares Out	437.02M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,668,088
Average Volume	1,116,219
Open	2.350
Previous Close	2.200
Day's Range	2.200 - 2.500
52-Week Range	2.050 - 15.500
Beta	1.80
RSI	28.78
Earnings Date	Apr 1, 2026

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company’s products are used in kidney disease diagnosis and prognosis, cl...

• Industry: Medical - Healthcare Information Services
• Sector: Healthcare
• Founded: 2018
• Employees: 46
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: RENX

Financial Performance

In fiscal year 2025, Renalytix's revenue was $3.00 million, an increase of 30.43% compared to the previous year's $2.30 million. Losses were -$20.40 million, -55.16% less than in 2024.

Financial numbers in USD